Sample size determination in clinical trials with multiple co-primary binary endpoints

被引:46
|
作者
Sozu, Takashi [1 ,2 ]
Sugimoto, Tomoyuki [2 ]
Hamasaki, Toshimitsu [1 ,2 ]
机构
[1] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate Bernoulli; association measures; continuity correction; arcsine transformation; Fisher's exact method; EFFICACY; DESIGN; ISSUES; POWER;
D O I
10.1002/sim.3972
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:2169 / 2179
页数:11
相关论文
共 50 条
  • [1] Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
    Wu, Beilei
    de Leon, Alexander R.
    BIOMETRICAL JOURNAL, 2013, 55 (05) : 807 - 812
  • [2] Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (04) : 650 - 668
  • [3] Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    BIOMETRICAL JOURNAL, 2012, 54 (05) : 716 - 729
  • [4] Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
    Huang, Wong-Shian
    Hung, Hui-Nien
    Hamasaki, Toshimitsu
    Hsiao, Chin-Fu
    PLOS ONE, 2017, 12 (06):
  • [5] "Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables" Reply
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    BIOMETRICAL JOURNAL, 2013, 55 (05) : 813 - 813
  • [6] Sample size determination in group-sequential clinical trials with two co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Hayashi, Kenichi
    Evans, Scott R.
    Sozu, Takashi
    STATISTICS IN MEDICINE, 2014, 33 (17) : 2897 - 2913
  • [7] A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints
    Sugimoto, Tomoyuki
    Sozu, Takashi
    Hamasaki, Toshimitsu
    PHARMACEUTICAL STATISTICS, 2012, 11 (02) : 118 - 128
  • [8] Power analysis for cluster randomized trials with multiple binary co-primary endpoints
    Li, Dateng
    Cao, Jing
    Zhang, Song
    BIOMETRICS, 2020, 76 (04) : 1064 - 1074
  • [9] Sample size determination for clinical trials with co-primary outcomes: exponential event?times
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Evans, Scott
    Sozu, Takashi
    PHARMACEUTICAL STATISTICS, 2013, 12 (01) : 28 - 34
  • [10] Evaluating Co-primary Endpoints Collectively in Clinical Trials
    Li, Qian H.
    BIOMETRICAL JOURNAL, 2009, 51 (01) : 137 - 145